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Conclusion: This study highlights the importance of the evaluation of surgi-
cal margins and staging (EPE) as influencing factors in the biochemical pro-
gression of prostate carcinoma. It also allows the comparisonwith internation-
al series and construction of guidelines for post-RP prognostic evaluation.
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Background & Objectives: Prostate cancer is the most common malig-
nant tumour of the male reproductive organs. Its course depends on the
histological and immunohistochemical characteristics of neoplasias. In
view of this, the purpose of study was to investigate the influences of
prostate cancer differentiation on peculiarities of Ki-67 and p53
expression.
Methods:The research was conducted on acinar prostate cancer cases
which were graded according to Gleason Score. The presence of p53
(SP5–1μg/ml) and Ki-67 (SP6–0.5μg/ml) receptors was detected by the
immunohistochemistry.
Results: Immunohistochemically in prostate cancer tissues it was re-
vealed different p53 andKi-67 expressions in tumours. Despite the strong
correlation between them, they didn't depend on the Gleason's grade. It
should be noted, that significantly higher their expression was found in
5th Gleason's grade comparing with others. Moreover, in 5th grade group
there are two kinds of tumour tissue: 1. with over-expression of p53/Ki-
67 and significant cellular atypia; 2. with low level of p53/Ki-67 expres-
sion and without cellular polymorphism.
Conclusion: The increase of Gleason's grade in prostate cancer tissue is
not accompanied by the direct enhance of Ki-67 and p53 expression. The
morphological evaluation of cancer tissue should include as Gleason's
grade as cellular atypia due to different expression of these proteins for
5th Gleason's grade tumours.
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Background & Objectives: Lynch syndrome (LS) patients develop up-
per tract urothelial carcinoma (UTUC) in 4-6% of cases and urothelial
bladder carcinoma (UBC) in 0-5%. Although it is well documented that
1-3% of all UTUCs are associated with LS, the frequency of LS among
UBC cases is not well known. This study assessed the frequency of
mismatch repair (MMR) protein expression loss (as a LS screening test)
in a large series of cases with muscle-invasive UBC (MI-UBC).
Methods: Review of medical records from 16 Spanish hospitals identi-
fied 540 muscle-invasive UBC cases. Sixteen tissue microarrays (TMAs)
were built and immunostained for MSH2, MSH6, MLH1 and PMS2.
TMAs were built with tumour specimens obtained by either radical
cystectomy without prior neoadjuvant therapy (n=404) or diagnostic
transurethral resection (TUR) (n=136). TMA negativity for PMS2 and
MSH6 staining was confirmed on whole sections. Two expert patholo-
gists (CC, EM) reviewed all slides.
Results: Only one out of 536 evaluable UBC cases showed loss of ex-
pression for both MMR proteins. The patient was a 40-year-old man
whose LS diagnosis (confirmed by sequencing, with a germline MSH2
mutation) was known at the time of UBC TUR.
Conclusion: As shown in the literature, frequency of MI-UBC in the
context of LS is very low. Our results indicate that implementation of a
universal LS testing algorithm to detect such an uncommon occurrence is
not necessary in patients with MI-UBC cases. Nevertheless, MMR pro-
tein expression analysis is recommended for younger patients or those
suffering from a LS-related condition.
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Background & Objectives: Patients with benign prostatic hyperplasia
(BPH) and transurethral resection of the prostate (TURP) are able to
detect incidental early stage prostate cancers (PrCa), which can not be
detected by clinical examination and / or imaging. In our study, we in-
vestigated whether there was a significant difference in the PrCa detection
rate, age between tumour detection and non-detection, histopathologic
examination of prostate tissue volume and serum PSA levels after
TURP for BPH in our study.
Methods: Between 2011 and 2018, 391 patients who underwent TURP
due to BPH in our hospital were included in the study.
Results: After histopathological examination, 17 of 391 patients (4.3%)
had incidental PrCa. The mean age was 69.5 (26-93) in cases with no
tumours and the mean age was 74,5 (54-93) in cases with PrCa. When the
tumours were classified according to age groups, two cases between 50-
60 years, two between 61-70 years, eight between 71-80 years, 5 cases
over 80 years were observed. Preoperative serum PSA levels were mea-
sured and mean PSA level was 5.05 ng / mL in 226 of the non-tumour
cases. Pre-operative serum PSA levels of 15 cases with tumour were
measured and the mean value was 4.46 ng / mL (0.40-28.5).
Conclusion: In our study, incidence of incidental PrCa detection (<5%)
in TURPmaterials for BPHwas found to be in parallel with the literature.
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